These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16932517

  • 1. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC.
    Nat Clin Pract Neurol; 2006 Jan; 2(1):24-5. PubMed ID: 16932517
    [No Abstract] [Full Text] [Related]

  • 2. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K, Hornnes N, Boysen G.
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D, Hill MD.
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [Abstract] [Full Text] [Related]

  • 6. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [Abstract] [Full Text] [Related]

  • 7. Effects of eprosartan on target organ protection.
    de la Sierra A.
    Vasc Health Risk Manag; 2006 Nov; 2(1):79-85. PubMed ID: 17319472
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
    Bloch MJ, Basile J.
    J Clin Hypertens (Greenwich); 2005 Aug; 7(8):489-92. PubMed ID: 16103761
    [No Abstract] [Full Text] [Related]

  • 10. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 11. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S, Hammersen F, Kulschewski A, Frerichs A, Frieg R, Hahnheiser D, Reich G, Schnieders M, Schrandt G, Schrader J.
    Dtsch Med Wochenschr; 2006 Nov 17; 131(46):2580-5. PubMed ID: 17096303
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B.
    Value Health; 2009 Sep 17; 12(6):857-71. PubMed ID: 19508663
    [Abstract] [Full Text] [Related]

  • 13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 17; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 14. Eprosartan: a review of its use in hypertension.
    Plosker GL.
    Drugs; 2009 Jul 17; 69(17):2477-99. PubMed ID: 19911859
    [Abstract] [Full Text] [Related]

  • 15. Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
    Cardiovasc J S Afr; 2005 Jul 17; 16(1):56. PubMed ID: 15778775
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov 17; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 18. Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
    Cardiovasc J S Afr; 2004 Nov 17; 15(5):255-6. PubMed ID: 15483740
    [No Abstract] [Full Text] [Related]

  • 19. MOSES raises questions.
    Strauss MH, Verma S.
    Stroke; 2006 Feb 17; 37(2):338-9; author reply 339-40. PubMed ID: 16397172
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.